TELEFLEX INC

Teleflex is a global provider of medical technology products that enhance clinical benefits, improve patient and provider safety and reduce total procedural costs. The company primarily designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for common diagnostic and therapeutic procedures in critical care and surgical applications. Because its products are used in numerous markets and for a variety of procedures, Teleflex is not dependent upon any one end-market or procedure. The medical device industry is highly competitive, characterized by extensive product research and development and rapid technological advances.

Teleflex competes with many domestic and foreign medical device companies ranging from small start-up enterprises to companies that are larger and more established with access to significantly greater financial and marketing resources. The company believes it competes primarily on the basis of clinical superiority and innovative features that enhance patient benefit, product reliability, performance, customer and sales support, and cost-effectiveness. The filing does not name specific competitors or provide market share percentages.

Teleflex generates revenue primarily from the sale of medical devices including single use disposable devices and, to a lesser extent, reusable devices, instruments and capital equipment. Revenue is recognized when obligations under the terms of a contract with the customer are satisfied, which generally occurs upon the transfer of control of the products at the point in time when products are shipped from the manufacturing or distribution facility. The company markets and sells products through its direct sales force and distributors to hospitals and healthcare providers worldwide. Substantially all net revenues come from single-use medical devices.

Teleflex's product categories within its geographic segments include Vascular and Emergency Medicine, Interventional, and Surgical. The Vascular product portfolio comprises devices designed to support a variety of critical care therapies with an emphasis on reducing vascular-related complications, including Arrow branded catheters, catheter navigation and tip positioning systems, intraosseous access systems (EZ-IO and Arrow FAST1), and hemostatic products (QuikClot). The Interventional product category offers devices for diagnosing and treating coronary and peripheral vascular disease, including a portfolio of Arrow branded catheters, GuideLiner, Turnpike and TrapLiner catheters, the MANTA Vascular Closure device, Arrow OnControl powered bone biopsy system, and, following the June 30, 2025 acquisition, a broad suite of coronary and peripheral medical devices such as drug-coated balloons, stents, and balloon catheters from the VI Business. The Surgical product category consists of single-use and reusable devices for various surgical procedures, including metal and polymer ligating clips, fascial closure surgical systems, percutaneous surgical systems, a powered bariatric stapler, and other surgical instruments, with brands including Weck, MiniLap, Pleur-Evac, Deknatel, KMedic, Pilling and Titan SGS.

On June 30, 2025, Teleflex acquired substantially all of the Vascular Intervention business of BIOTRONIK SE & Co. KG for a net initial cash payment of €704.3 million, or $825.2 million ¹, subject to certain working capital and other customary adjustments. On December 9, 2025, Teleflex announced definitive agreements to sell its Acute Care and Interventional Urology businesses to Intersurgical Ltd and its OEM business to Montagu and Kohlberg (the Strategic Divestitures) for combined total consideration of $2.0 billion in cash ², consisting of expected proceeds of approximately $1.5 billion ³ for the OEM business and $530 million ⁴ for the Acute Care and IU businesses. On February 28, 2025, Teleflex executed an accelerated share repurchase agreement for $300 million ⁵ of its common stock, and on December 9, 2025, the Board of Directors authorized a share repurchase program for up to $1.0 billion ⁶ of common stock. During the third quarter of 2025, Teleflex recognized an impairment charge of $100.0 million ⁷ related to its Titan SGS asset group. On January 8, 2026, the company announced the departure of its Chairman, President and CEO, Liam J. Kelly, and the appointment of Stuart A. Randle as Interim President and CEO.

Net revenues for the year ended December 31, 2025 increased by $293.2 million, or 17.2% ⁸, compared to the prior year, primarily due to net revenues of $202.4 million ⁹ generated by the acquired VI Business. Gross margin decreased 480 basis points, or 7.9% ¹⁰, to 56.2% ¹¹ compared to 61.0% ¹² in the prior year. Income from continuing operations was $58.5 million ¹³ compared to $57.2 million ¹⁴ in the prior year. Net loss was $905.6 million ¹⁵ compared to net income of $69.7 million ¹⁶ in the prior year, driven by losses from discontinued operations of $964.2 million ¹⁷. Net cash provided by operating activities from continuing operations was $96.7 million ¹⁸ during 2025 compared to $301.9 million ¹⁹ during 2024.

The acquisition of the VI Business adds a broad suite of coronary and peripheral medical devices, such as drug-coated balloons, stents, and balloon catheters, which complement Teleflex's interventional product portfolio. The company expects to achieve annual pre-tax savings of $24 million to $30 million ²⁰ in connection with the VI Business integration plan once it is fully implemented and expects to begin realizing a portion of these plan-related savings in 2026. The Strategic Divestitures represent a plan to exit certain product categories and focus on the remaining businesses; the company expects to receive net after-tax proceeds of approximately $1.8 billion ²¹ upon the completion of both sales and intends to use the net proceeds primarily to return capital to shareholders through share repurchases and pay down debt.

The Strategic Divestitures restructuring plan, initiated in the first quarter of 2026, is intended to eliminate stranded costs, streamline global operations, and improve the long-term cost structure. Teleflex expects to achieve annual pre-tax savings of $48 million to $52 million ²² in connection with this plan once it is fully implemented and expects to begin realizing a portion of these plan-related savings in 2026.

Teleflex continues to execute its footprint realignment and other restructuring programs designed to improve efficiencies in its manufacturing and distribution facilities. The company is in the early stages of a multi-year phased conversion to upgrade its global ERP system. The VI Business integration plan encompasses the realignment of the global sales force and certain administrative functions, including workforce reductions, and the relocation of certain manufacturing operations to existing lower-cost locations, with actions expected to be substantially completed by the end of 2028.

For the year ended December 31, 2025, capital expenditures from continuing operations were $95.2 million ²³. The company expects to incur $5 million to $7 million ²⁴ in aggregate capital expenditures under the VI Business integration plan, expected to be incurred mostly between 2026 and 2027. On December 9, 2025, the Board of Directors authorized a share repurchase program for up to $1.0 billion ²⁵ of common stock. Dividends paid during 2025 were $60.3 million ²⁶.

The healthcare industry has been adversely affected by government-led initiatives intended to reduce healthcare product costs, such as China's volume-based procurement programs, which have impacted and may further impact results. Recently enacted U.S. tariffs and accompanying retaliatory measures have adversely impacted results, primarily due to higher import costs associated with operations in the European Union and products manufactured in Mexico that are not currently compliant with USMCA. The company also continues to monitor impacts from currency exchange rate fluctuations, changes in interest rates, and ongoing geopolitical conflicts.

The company faces risks from the strategic transformation and Strategic Divestitures, which may not achieve the anticipated benefits and could result in significant expenses; the combined total consideration is $2.0 billion in cash ²⁷. The company is subject to extensive government regulation, and failure to comply could result in sanctions including product seizures, recalls, or shutdown of manufacturing. Disruptions in sterilization of products using ethylene oxide, particularly at Sterigenics facilities, could impair the ability to provide affected products; sterilizers must comply with new EPA standards by April 6, 2026 or April 5, 2027 ²⁸. The company has substantial indebtedness of $2.7 billion ²⁹ as of December 31, 2025, which could limit flexibility and increase vulnerability to economic conditions. Foreign currency risk is significant; a hypothetical 10% increase/decrease in the U.S. dollar against all currencies would change the fair value of foreign currency forward and cross-currency swap contracts by $179.5 million ³⁰ and $182.2 million ³¹, respectively.

Management's message emphasizes the strategic transformation of the organization, announced in February 2025, and the execution of definitive agreements to divest the Acute Care, Interventional Urology, and OEM businesses. The combined total consideration from the Strategic Divestitures is $2.0 billion in cash ³², consisting of expected proceeds of approximately $1.5 billion ³³ for the OEM business and $530 million ³⁴ for the Acute Care and IU businesses. Management states the intention to use the net proceeds primarily to return capital to shareholders through share repurchases and pay down debt. The strategic priorities emphasized include completing the Strategic Divestitures, integrating the acquired VI Business, and executing restructuring programs to improve long-term cost structure and eliminate stranded costs.